Plain-English translation of NCT07320105 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether adding radiation therapy to a combination of Tislelizumab (an immunotherapy drug) and chemotherapy helps people recover better after surgery for advanced lung cancer. Some patients will receive the immunotherapy and chemotherapy alone, while others will also receive focused radiation to the area where cancer was found. The goal is to see which approach works best at preventing the cancer from coming back.
Even after surgery, many people with this type of advanced lung cancer experience cancer recurrence. Researchers want to know if adding radiation to the newer immunotherapy approach can help keep the cancer from returning and improve survival rates.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of two groups: one group receives immunotherapy combined with chemotherapy, and the other group receives the same medications plus focused radiation therapy to the surgical site. You will receive intravenous medications on a regular schedule and, depending on your group, may also have radiation treatments over several weeks. Throughout the trial, you'll have blood tests and imaging scans to monitor your response and check for side effects.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
China